.png)
Mid-Size Biopharma
Medical Affairs, Market Access, HEOR, Commercial
Phase III
Neurology
Subscribe to our newsletter to receive the latest case studies.
Mid-Size Biopharma
Medical Affairs, Market Access, HEOR, Commercial
Phase III
Neurology
A mid-size biopharma company was preparing to launch a novel therapy, with Phase III trials underway.
While development was progressing, teams lacked clarity on which outcomes would matter most to payers and how existing evidence supported a compelling value case.
The client engaged Alkemi to define the payer value story, identify critical evidence gaps, and align evidence generation and communication plans ahead of launch.
1. Conducted targeted literature reviews to assess available evidence across disease burden, clinical outcomes, safety, economic impact, and quality of life.
2. Mapped payer-relevant value messages to existing evidence to identify strengths and gaps.
3. Facilitated a cross-functional workshop to refine the value story, prioritize evidence gaps, and align on data generation needs.
4. Developed a practical evidence generation roadmap aligned with Phase III plans and future access requirements.
Ensure Phase III evidence supports payer decisions at launch.
"They helped us identify our evidence gaps and develop a solid plan that aligned us with payer expectations and strengthened our evidence strategy." - Head of Medical Affairs
Teams aligned on what value drivers would matter most to payers at launch.
Phase III data generation was prioritized to address critical access questions.
A clear value story and roadmap positioned the client to support access and pricing discussions from day one.